- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/10 | 14.9 | 13.55 | -13.55 | 155.94 | 2.92 | 44.36 | N/A | - | ||
2024/9 | 13.12 | -19.71 | -17.3 | 141.04 | 5.03 | 50.79 | 0.69 | - | ||
2024/8 | 16.34 | -23.38 | 4.51 | 127.92 | 8.02 | 51.14 | 0.68 | - | ||
2024/7 | 21.33 | 58.38 | 36.54 | 111.57 | 8.56 | 51.06 | 0.69 | - | ||
2024/6 | 13.47 | -17.16 | 12.22 | 90.24 | 3.54 | 46.01 | 0.68 | - | ||
2024/5 | 16.26 | -0.14 | 11.13 | 76.78 | 2.15 | 46.99 | 0.66 | - | ||
2024/4 | 16.28 | 12.68 | 15.24 | 60.52 | 0.0 | 44.37 | 0.7 | - | ||
2024/3 | 14.45 | 5.93 | -5.06 | 44.23 | -4.65 | 44.23 | 0.8 | - | ||
2024/2 | 13.64 | -15.49 | -14.58 | 29.78 | -4.45 | 42.37 | 0.84 | - | ||
2024/1 | 16.14 | 28.27 | 6.18 | 16.14 | 6.18 | 43.39 | 0.82 | - | ||
2023/12 | 12.58 | -14.2 | -21.15 | 178.77 | -23.44 | 44.49 | 0.62 | - | ||
2023/11 | 14.67 | -14.9 | -16.63 | 166.18 | -23.61 | 47.77 | 0.58 | - | ||
2023/10 | 17.24 | 8.63 | -23.22 | 151.51 | -24.22 | 48.74 | 0.57 | - | ||
2023/9 | 15.87 | 1.46 | -25.41 | 134.28 | -24.35 | 47.12 | 0.56 | - | ||
2023/8 | 15.64 | 0.09 | -29.43 | 118.41 | -24.2 | 43.26 | 0.61 | - | ||
2023/7 | 15.62 | 30.17 | -33.53 | 102.78 | -23.34 | 42.25 | 0.63 | - | ||
2023/6 | 12.0 | -17.97 | -37.1 | 87.15 | -21.17 | 40.76 | 0.72 | - | ||
2023/5 | 14.63 | 3.54 | -25.59 | 75.15 | -17.85 | 43.98 | 0.67 | - | ||
2023/4 | 14.13 | -7.17 | -28.3 | 60.52 | -15.73 | 45.32 | 0.65 | - | ||
2023/3 | 15.22 | -4.69 | -15.99 | 46.39 | -10.97 | 46.39 | 0.71 | - | ||
2023/2 | 15.97 | 5.06 | 3.35 | 31.17 | -8.3 | 47.13 | 0.7 | - | ||
2023/1 | 15.2 | -4.75 | -18.02 | 15.2 | -18.02 | 48.76 | 0.68 | - | ||
2022/12 | 15.96 | -9.28 | 21.86 | 233.51 | -5.21 | 56.01 | 0.57 | - | ||
2022/11 | 17.59 | -21.63 | -62.88 | 217.55 | -6.73 | 61.32 | 0.52 | 2021年11月與Genzyme 就被授權之歐洲及美國專利權所生之歐洲與美國權利金爭議達成和解,故於2021年11月認列權利金收入。 | ||
2022/10 | 22.45 | 5.54 | 34.31 | 199.95 | 7.58 | 65.88 | 0.49 | - | ||
2022/9 | 21.27 | -4.0 | 32.08 | 177.5 | 4.94 | 66.93 | 0.54 | - | ||
2022/8 | 22.16 | -5.71 | 1.17 | 156.23 | 2.08 | 64.74 | 0.56 | - | ||
2022/7 | 23.5 | 23.18 | 25.86 | 134.07 | 2.23 | 62.25 | 0.58 | - | ||
2022/6 | 19.08 | -2.97 | -2.4 | 110.57 | -1.68 | 58.45 | 0.57 | - | ||
2022/5 | 19.66 | -0.23 | 3.72 | 91.49 | -1.53 | 57.49 | 0.58 | - | ||
2022/4 | 19.71 | 8.78 | -2.84 | 71.82 | -2.88 | 53.28 | 0.63 | - | ||
2022/3 | 18.12 | 17.25 | -3.36 | 52.11 | -2.89 | 52.11 | 0.59 | - | ||
2022/2 | 15.45 | -16.67 | -1.72 | 34.0 | -2.64 | 47.09 | 0.66 | - | ||
2022/1 | 18.54 | 41.58 | -3.4 | 18.54 | -3.4 | 79.04 | 0.39 | - | ||
2021/12 | 13.1 | -72.36 | -26.33 | 246.35 | 43.86 | 77.21 | 0.36 | - | ||
2021/11 | 47.4 | 183.55 | 191.69 | 233.26 | 52.0 | 80.22 | 0.35 | 與Genzyme 就被授權之歐洲及美國專利權所生之歐洲與美國權利金爭議達成和解,故本月認列權利金收入。 | ||
2021/10 | 16.72 | 3.79 | 8.93 | 185.86 | 35.45 | 54.72 | 0.51 | - | ||
2021/9 | 16.1 | -26.46 | 3.94 | 169.14 | 38.79 | 56.68 | 0.41 | - | ||
2021/8 | 21.9 | 17.28 | 14.72 | 153.04 | 43.87 | 60.12 | 0.39 | - | ||
2021/7 | 18.67 | -4.47 | 27.85 | 131.14 | 50.24 | 57.18 | 0.41 | 109年受到疫情影響停工,銷量減少,110年疫情趨緩,銷量增加,致營收增加。 | ||
2021/6 | 19.55 | 3.12 | 66.33 | 112.46 | 54.74 | 58.79 | 0.35 | 109年因疫情影響,營收減少,110年因疫情趨緩,營收增加 | ||
2021/5 | 18.96 | -6.54 | 109.32 | 92.91 | 52.51 | 57.99 | 0.36 | 109年因疫情影響,營收減少,110年因疫情趨緩,營收增加 | ||
2021/4 | 20.29 | 8.2 | 181.42 | 73.96 | 42.59 | 54.76 | 0.38 | 109年受到疫情影響停工,銷量減少,110年疫情趨緩,銷量增加,致營收增加。 | ||
2021/3 | 18.75 | 19.24 | 22.78 | 53.67 | 20.18 | 53.67 | 0.53 | - | ||
2021/2 | 15.72 | -18.1 | 7.06 | 34.92 | 18.82 | 52.7 | 0.54 | - | ||
2021/1 | 19.2 | 7.98 | 30.57 | 19.2 | 30.57 | 53.23 | 0.54 | - | ||
2020/12 | 17.78 | 9.41 | 903.0 | 171.24 | -23.11 | 49.37 | 0.45 | 本月營收較同期增加,係108年12月當期調減108年第2季到第4季未收到之權利金收入所致。 | ||
2020/11 | 16.25 | 5.89 | -2.59 | 153.46 | -30.54 | 47.09 | 0.47 | - | ||
2020/10 | 15.34 | -0.95 | -11.36 | 137.21 | -32.82 | 49.93 | 0.44 | - | ||
2020/9 | 15.49 | -18.84 | -17.91 | 121.86 | -34.81 | 49.19 | 0.47 | - | ||
2020/8 | 19.09 | 30.7 | -20.95 | 106.37 | -36.71 | 45.45 | 0.51 | - | ||
2020/7 | 14.61 | 24.26 | -30.81 | 87.28 | -39.35 | 35.41 | 0.65 | - | ||
2020/6 | 11.75 | 29.77 | -41.88 | 72.67 | -40.82 | 28.02 | 1.0 | - | ||
2020/5 | 9.06 | 25.63 | -57.3 | 60.92 | -40.61 | 31.53 | 0.89 | 營收較去年同期減少,係因受到疫情影響,銷量減少所致 | ||
2020/4 | 7.21 | -52.79 | -65.14 | 51.87 | -36.26 | 37.16 | 0.75 | 營收較上期、去年同期減少,係因受疫情停工影響,銷量減少,以致營收減少 | ||
2020/3 | 15.27 | 3.97 | -27.21 | 44.66 | -26.41 | 44.66 | 0.66 | - | ||
2020/2 | 14.69 | -0.11 | -18.56 | 29.39 | -25.99 | 31.16 | 0.95 | - | ||
2020/1 | 14.7 | 729.44 | -32.18 | 14.7 | -32.18 | 33.16 | 0.89 | - | ||
2019/12 | 1.77 | -89.37 | -90.96 | 222.71 | -8.83 | 0.0 | N/A | 係原合併營收公告數與會計師查核數差異,請參閱109/3/20序號5重訊之說明 | ||
2019/11 | 16.68 | -3.63 | -19.07 | 220.94 | -1.66 | 0.0 | N/A | - |
年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
---|---|---|---|---|---|---|---|---|---|
2024/1 | 16.14 | 2023/1 | 15.2 | 2022/1 | 18.54 | 2021/1 | 19.2 | 2020/1 | 14.7 |
2024/2 | 13.64 | 2023/2 | 15.97 | 2022/2 | 15.45 | 2021/2 | 15.72 | 2020/2 | 14.69 |
2024/3 | 14.45 | 2023/3 | 15.22 | 2022/3 | 18.12 | 2021/3 | 18.75 | 2020/3 | 15.27 |
2024/4 | 16.28 | 2023/4 | 14.13 | 2022/4 | 19.71 | 2021/4 | 20.29 | 2020/4 | 7.21 |
2024/5 | 16.26 | 2023/5 | 14.63 | 2022/5 | 19.66 | 2021/5 | 18.96 | 2020/5 | 9.06 |
2024/6 | 13.47 | 2023/6 | 12.0 | 2022/6 | 19.08 | 2021/6 | 19.55 | 2020/6 | 11.75 |
2024/7 | 21.33 | 2023/7 | 15.62 | 2022/7 | 23.5 | 2021/7 | 18.67 | 2020/7 | 14.61 |
2024/8 | 16.34 | 2023/8 | 15.64 | 2022/8 | 22.16 | 2021/8 | 21.9 | 2020/8 | 19.09 |
2024/9 | 13.12 | 2023/9 | 15.87 | 2022/9 | 21.27 | 2021/9 | 16.1 | 2020/9 | 15.49 |
2024/10 | 14.9 | 2023/10 | 17.24 | 2022/10 | 22.45 | 2021/10 | 16.72 | 2020/10 | 15.34 |
N/A | N/A | 2023/11 | 14.67 | 2022/11 | 17.59 | 2021/11 | 47.4 | 2020/11 | 16.25 |
N/A | N/A | 2023/12 | 12.58 | 2022/12 | 15.96 | 2021/12 | 13.1 | 2020/12 | 17.78 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
合約負債 QoQ YoY |
---|